

Lubor Golan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7997200/publications.pdf>

Version: 2024-02-01

15
papers

290
citations

1162367

8
h-index

1058022

14
g-index

19
all docs

19
docs citations

19
times ranked

467
citing authors

#	ARTICLE	IF	CITATIONS
1	The Cost-Effectiveness of Treating All Patients with Type 2 Diabetes with Angiotensin-Converting Enzyme Inhibitors. <i>Annals of Internal Medicine</i> , 1999, 131, 660.	2.0	126
2	Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS). <i>Journal of Inherited Metabolic Disease</i> , 2014, 37, 455-460.	1.7	47
3	Replacement of α -galactosidase A in Fabry disease: effect on fibroblast cultures compared with biopsied tissues of treated patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008, 452, 651-665.	1.4	29
4	The coincidence of IgA nephropathy and Fabry disease. <i>BMC Nephrology</i> , 2013, 14, 6.	0.8	15
5	Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease. <i>Drug Design, Development and Therapy</i> , 2015, 9, 3435.	2.0	15
6	Association between tyrosine hydroxylase polymorphisms and left ventricular structure in young normotensive men. <i>British Journal of Biomedical Science</i> , 2002, 59, 90-94.	1.2	9
7	Fabry disease - Vascular manifestations. <i>Vasa - European Journal of Vascular Medicine</i> , 2010, 39, 123-131.	0.6	9
8	The development of persistent thrombotic masses in patients with deep venous thrombosis randomized to long-term anticoagulation treatment. <i>Vasa - European Journal of Vascular Medicine</i> , 2009, 38, 238-244.	0.6	7
9	Pitfalls of X-chromosome inactivation testing in females with Fabry disease. <i>American Journal of Medical Genetics, Part A</i> , 2022, 188, 1979-1989.	0.7	5
10	Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease. <i>PLoS ONE</i> , 2016, 11, e0166290.	1.1	4
11	Serum Bilirubin Levels and Promoter Variations in <i>HMOX1</i> and <i>UGT1A1</i> Genes in Patients with Fabry Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-6.	1.9	3
12	Normative reference ranges for echocardiographic chamber dimensions in a healthy Central European population: results from the Czech post-MONICA survey. <i>Cardiovascular Ultrasound</i> , 2019, 17, 22.	0.5	3
13	Migalastat in the treatment of Fabry disease. <i>Interni Medicina Pro Praxi</i> , 2017, 19, 167-170.	0.0	1
14	Fabry disease. <i>Interni Medicina Pro Praxi</i> , 2018, 20, 10-13.	0.0	0
15	Cardiologic evaluation in Fabry disease. <i>Intervencni A Akutni Kardiologie</i> , 2018, 17, 67-70.	0.0	0